Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Pfizer Pushes Back Champix Re-Supply Plan on Regulatory Delay
Pfizer Japan is postponing its re-supply of the smoking cessation aid Champix (varenicline), previously scheduled for the first half of 2025, due to stalling regulatory reviews. The suspension has been in place for already four years, and the issue looks…
To read the full story
Related Article
- Pfizer Resumes Supply of Smoking Cessation Pill Champix after 4 Years
October 31, 2025
- 50% of Quit-Smoking Clinics Closed or Suspended, Will Champix Re-Supply Bring Them Back Online?
October 30, 2024
- Pfizer Japan Seeks Partial Change of Champix’s Approval towards Re-Supply
September 2, 2024
- Nitrosamine Impurity Detected in Sitagliptin, Shipments in Japan to Continue with FDA-Set Limit: MSD/Ono
September 2, 2022
- Pfizer Continues to Halt Champix Shipments on Prolonged Fix of Manufacturing Process
August 24, 2022
- Pfizer Japan Recalling Some Champix Products after Detecting Carcinogen
July 29, 2021
BUSINESS
- GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
- Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
July 3, 2026
- PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…